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ABSTRACT 
 
 
Tau is a microtubule-associated protein mainly expressed in neurons, encoded by 
the MAPT gene. Mutations in the MAPT locus lead to abnormal accumulation of 
hyperphosphorylated tau in abundant intracellular inclusions known as 
neurofibrillary tangles (NFTs), a common feature of a group of neurodegenerative 
diseases known as Tauopathies. 
In order to characterize the effect of ΔK280 and Q336H MAPT mutations FRET and 
FRAP techniques have been employed. To this aim the Conformational-Sensitive 
Tau Sensor (CST) that is based on the full length tau isoform 4R0N with the ECFP 
fused at the N-terminus and the EYFP at the C-terminus have been used. Since the 
CST allows to evaluate the changing in protein conformation and   tau interactions 
with microtubules in living cells, two mutated CST constructs have been generated.   
The study has revealed that Q336H and ΔK280 induced conformational changes in 
tau protein. In particular, Q336H alters the conformation by allowing the two ends of 
Tau protein to approach each other in a more closed loop-like structure. On the 
contrary, ΔK280 determined a conformational change by inducing a more relaxed 
three-dimensional structure and altered Tau stability on Microtubules by increasing 
the soluble Tau protein. 
 
 
 
 
 
 
 
 
 
6 
 
INTRODUCTION 
 
1.Tauopathies 
 
Alois Alzheimer (1907) firstly described the existence in brain of intracellular 
neurofibrillary tangles (NFTs) associated with extracellular plaques and only a few 
years later the presence of intracellular inclusions alone in different case of 
dementia. NFTs were first isolated from frozen autopsied AD brains. In 1963 Kid 
and Terry independently reported that they were made up of abnormal filaments 
alternating between 15 (at their narrowest point) and 30 nm (at their widest point) in 
width. Because it appeared that these filaments were wound in one another they 
were called paired helical filaments (PHF). They also found in NFT straight filament 
(SF), about 15nm wide. Years after, a protein of ~50kDa was isolated as the main 
constituent of PHF, but only in 1986 this protein was identified to be the 
Microtubule-Associated Protein Tau, and in 1988 the MAPT gene was cloned. 
Tau is a microtubule-associated protein mainly expressed in neurons, encoded by 
the MAPT gene on chromosome 17q21-22. In a normal human brain are present 
six different isoforms, which differs mainly for the presence or absence of two 
inserts of about 29-58 aa in the N-terminal part, depending on the differential 
splicing of exons 2-3, and for the presence of three or four MTR at the C-terminal, 
depending on the differential splicing of exon 10. The differential splicing gives rise 
to three isoforms with three binding repeats (3R) or to four isoforms with four 
binding repeats (4R). The longest isoform of tau contains 80 sites of potential 
phosphorylation composed by serine and threonine residues, followed by a proline, 
almost all located in the regions flanking the microtubule binding repeats, as will be 
discussed further, and different tauopathies have shown to have different 
immunoreactivities to different tau phosphorylation epitopes, according to the 
immunohistochemistry analysis carried on fixed brain tissues. 
Primary tauopathies are a heterogeneous group of neurodegenerative diseases 
that shares as a common feature the presence in neuronal and glial cells of 
deposits of misfolded, insoluble and hyperphosphorylated tau proteins. They are 
considered a subgroup of pathologies associated with Frontotemporal Lobar 
Degeneration (FTLD), a group of non-Alzheimer degenerative dementias with focal 
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cortical neuronal loss and gliosis, Frontotemporal Lobar Degeneration-Tau (FTLD-
Tau) is their proper definition, used to differentiate them from other form of 
proteinopathies that fell under the FTLD spectrum. The age of onset is at 45-65 
years, with a mean average in the 50s, with equal prevalence among men and 
women. Clinically they present the same variants displayed by FTLD, such as 
behavior, executive and language impairment associated with atrophy of the 
temporal and frontal lobe, giving rise to behavioral variant of FTD (bvFTD), 
semantic dementia (SD), and progressive non-fluent aphasia (PNFA), often 
associated with parkinsonism and motor neuron disease (MND). Patients with bv-
FTD present dramatic changes in behavior and in personality, often displaying 
apathy and disinhibition, caused primarily by atrophy of the frontal cortex, with 
different region relating to different clinical phenotypes. Semantic Dementia is 
characterized by fluent anomic aphasia and behavioral changes, as a consequence 
of atrophy of the anterior temporal lobes, while Progressive non-fluent aphasia is 
characterized by a progressive disorder of speech and motor impairment, due to 
atrophy of the left frontal operculum. 
FTLD-Tau can be sporadic or familial, the latter caused by mutations in the MAPT 
gene, with great clinical and pathological heterogeneity, mainly due to the different 
impact that these mutations can have on the physiological function of tau, which is 
to promote the assembly and the stabilization of the microtubules (MTs) required for 
morphogenesis and axonal transport. Genetic and environmental risk factors that 
could trigger tau pathology in sporadic forms of FTLD are still a matter of debate. 
The discovery of a polymorphic inversion along the MAPT coding region (Baker et 
al., 1999) led to the definition of the H1/H2 haplotypes, in complete disequilibrium 
with each other,  with the H1 including the noninverted sequence and the H2 
comprising the inverted sequence and several other genes in its 900-kb length 
(Stefansson et al., 2005). They differ in nucleotide sequence and in intron site, but 
they are identical at amino acid level. The more common H1 haplotype is 
significantly overrepresented in patients with Progressive Sopranuclear Palsy (PSP) 
and Corticobasal Degeneration (CBD) (Baker et al., 1999; Houlden et al., 2001), 
while there is no difference between the H2 haplotype or the H2/H2 genotype 
observed in patients with Pick's Disease compared with control subjects (Morris et 
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al., 2002). Other studies also found an association between the H1 haplotype and 
the H1/H1 genotype with the development of sporadic FTD. One of the main region 
characterized by these polymorphisms is the promoter, altering the interaction with 
specific transcription factors and leading to tau expression deregulation. To further 
identify genetic variations contributing to the development of PSP, a GWAS study 
was carried out, and found significant signal associated with PSP risk in synthaxin 6 
(STX6), eukaryotic translation initiation factor 2-α kinase 3 (EIF2AK3), and myelin-
associated oligodendrocyte basic protein (MOBP) genes (Hoglinger et al., 2011). 
Hereditary forms of FTLD-Tau, which account for ~30% of FTD cases, are 
dependent on the presence of mutations in the MAPT locus, firstly associated with 
autosomal dominant inherited form of FTD with parkinsonism, leading to the 
definition of Frontotemporal Dementia with parkinsonism linked to chromosome 17 
(FTDP-17). Familial cases with MAPT mutations present a wide range spectrum of 
pathology, starting typically from atrophy of frontal and temporal lobes, astrogliosis, 
swollen neurons and neuronal loss. Often cases are pathologically consistent with 
sporadic tauopathies and requires genetic testing to prove that are caused by 
mutations in the MAPT locus. Anyway tau inclusions in neurons and glia are 
hyperphosphorylated and acetylated in both familial and sporadic diseases, even if 
tau can undergo several post-translational modifications that can contribute to 
disease pathogenesis, as will be discussed further. 
Finally, FTLD-Tau can be subdivided into several neuropathological diagnoses and 
classified based on the predominant tau isoforms that are present in the inclusion 
bodies. Because there is no involvement of the MAPT gene in the development of 
Alzheimer's disease, but other than the neurofibrillary tangles are also present 
senile plaques made of amyloid-beta protein, it is considered a “secondary 
tauopathy” belonging to the subgroup in which there is a balanced ratio of 3R and 
4R tau isoforms in the inclusions. 
Another feature that can help to discriminate between different tauopathies is the 
filament morphology, that have been studied in preparations of fixed tissues and 
dispersed filaments (Crowther et al., 2000). Tau filaments can be straight, ribbon-
like or paired-helical. A recent study (Taniguchi-Watanabe et al., 2016) found out 
that the C-terminal (residues 243-406) band pattern of the pathological tau species 
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is distinct for each disease. Employing analysis of sarkosyl-insoluble tau banding 
patterns using antibodies against tau C-terminus, tauopathies can be classified in at 
least four types, Pick Disease, Progressive Sopranuclear Palsy, Alzheimer's 
Disease, and Corticobasal Degeneration, even if it is also possible to extend this 
analysis to other tauopathies such Argyrophilic Grain Disease (AGD) and Globular 
Glial Tauopathy (GGT). They also discriminate that pathological 4R tau in MAPT 
intron mutation cases can be distinguishable from that in CBD and PSP cases by 
the analysis of the C-terminal fragments and the trypsin-resistant tau. A structurally 
distinct pathological tau protein seems to be involved in each disease and 
pathological proteins have the ability to convert normal tau into its own abnormal 
form. Indeed, the injection of brain homogenates from AD, PiD, CBD, PSP patients 
into Tg-mice overespressing 4R isoforms demonstrated that a similar pathology 
was induced (Clavaguera et al., 2013). 
 
1.1 Frontotemporal Dementia with Parkinsonism linked to chromosome 17 
 
Inherited forms of Frontotemporal Dementia were known from many years, but due 
to the clinic-pathological heterogeneity, the nomenclature has always been variable. 
The major clinical manifestations include cognitive impairment, behavioral 
disturbances, aphasia and parkinsonism. The discovery of mutations in the MAPT 
locus on the chromosome 17q21-22 led to the concept of Frontotemporal Dementia 
with Parkinsonism (FTDP-17) (Foster et al., 1997), which for a very long time it's 
also been used to name all of the pathologies that were found to be caused by 
mutations in that locus but that shown slightly different features, such as the 
inherited forms of Pick's disease; FTDP-17 also shows in its progression some 
features that are in common with Alzheimer's Disease, Progressive Sopranuclear 
Palsy, Corticobasal Degeneration, but neuropathology and neuroimaging allow to 
discriminate different clinical phenotypes. 
53 pathologic mutations have been reported in the MAPT locus (van der Zee et al., 
2014). FTDP-17 affects men and women equally, with the average age at onset 
being 49 years, with a range from the late 20s to the late 70s, similar to 
Frontotemporal Lobar Degeneration (FTLD). Its inheritance is autosomal dominant. 
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Differently from the other tauopathies, in FTDP-17 there isn't a prevalence of a tau 
isoform, mutations in the MAPT locus are heterogeneous and can cause the 
abnormal protein conformation or the disruption in 3R/4R ratio, or both, depending 
on the type of mutation. 
The neuropathological phenotype associated with FTDP-17 MAPT vary 
substantially; the only invariable hallmark is the presence in neurons, or in both 
neurons and glia, of tau inclusions. Tau inclusions are abundant in cerebral cortex 
and white matter; subcortical and brain stem nuclei, as the spinal cord, are variably 
affected, but their anatomical distribution has been reported with different details in 
relation to individual mutations, even if the information is always obtained for the 
late stages of pathology. There may be mild atrophy of the caudate nucleus and a 
reduction in the pigmentation of the substantia nigra and the locus coeruleus. In 
advanced stages, the degree of atrophy varies and may be present throughout the 
frontal and temporal lobes, caudate nucleus, putamen, globus pallidus, amygdala, 
hippocampus and hypothalamus. Most often, the superior, middle, and inferior 
frontal gyri, as well as the superior, middle, and inferior temporal gyri, bear the brunt 
of the disease, with the anterior portion of the temporal lobe being particularly 
vulnerable. Brain atrophy may involve the frontal and temporal lobes 
asymmetrically. 
As said before, the onset of FTDP-17 is insidious.Generally individuals shows three 
of the main cardinal symptoms, such as behavioral and personality disturbances, 
cognitive impairment and/or motor dysfunction. Clinical variability is seen in 
individuals with the same MAPT mutation, in different families or even within the 
same family. The behavioral and personality abnormalities include disinhibition, 
apathy, loss of empathy, aggressiveness, impulsive and/or compulsive behavior, 
lack of regard for personal hygiene, hyper orality including excessive use of alcohol 
and drugs. Progressive non fluent aphasia can be seen initially (Munoz et al., 
2007), and later progressive deterioration of memory, visual and spatial function, 
with development of a progressive dementia encompassing most cognitive domains 
that led the patient to completely lose the capacity of speaking. Parkinsonism 
associated with FTDP-17 MAPT is characterized by symmetrical bradykinesia, 
postural instability and rigidity affecting axial and appendicular musculatures, 
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absence of resting tremor, and poor or no responsiveness to levodopa. Even if no 
systematic work has been published on genotype-phenotype correlations in FTDP-
17 MAPT, there is a general accordance that exonic mutations that do not affect the 
splicing of exon 10 are usually associated with a dementia-predominant phenotype. 
In contrast, intronic and exonic mutations that affects exon 10 splicing and lead to 
an overproduction of 4R tau isoform tend to be associated with a parkinsonism plus 
predominant phenotype (Ghetti et al., 2015). 
 
1.2  Pick's disease 
 
Pick's Disease (PiD) is a progressive neurodegenerative disease that accounts for 
less than 5% dementia cases and usually occurs before 65 years of age. The most 
common clinical presentation is behavioral variant frontotemporal dementia, but 
language variants, both agrammatic and semantic types of primary progressive 
aphasia, have been reported. The diagnostic histological feature of Pick's disease 
are the Pick bodies, well-circumscribed, spherical, tau-immunoreactive and 
intracytoplasmic neuronal inclusions, which features the 3R tau isoform as the most 
prominent (Delacourte et al., 1996). A small number of inclusions appear to contain 
4R tau isoforms, as shown by IHC, and also to be thioflavine-S positive and to show 
immunoreactivity to acetylation-specific antibodies directed at K280 residue (Irwin 
et al, 2013). There are also swollen and achromatic “ballooned” neurons that are 
called Pick cells, prominent neuronal loss and astrocytosis. Pick bodies are found 
mostly in granule cells of the dentate gyrus, as well as the hippocampus and some 
cortical areas. Tau filaments are characterized by straight tubule of 15-18nm 
diameter and 22-24 nm diameter twisted filaments (Munoz et al., 1984). Pick 
Disease is usually sporadic, but discovery in mutations in the MAPT gene has 
contributed to the concept of hereditary forms of PiD, so it's also been associated 
with several clinical frontotemporal dementia (FTD) syndromes. 
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1.3 Progressive Supranuclear Palsy 
 
Progressive Supranuclear Palsy is a 4R predominant tauopathy which shows 
atrophy of the subthalamic nucleus and brainstem tegmentum, and depigmentation 
of the substantia nigra. NFTs are present in the subthalamic nucleus, basal ganglia 
and brainstem, that are variably but characteristically associated with tufted 
astrocytes, and oligodendroglial coiled bodies. Tau filaments, as revealed by 
ultrastructural examination, are characterized as in PiD by straight tubule of 15-18 
nm diameter and in NFTs by 14 nm diameter straight tubules (Arima, 2006; Dickson 
et al., 2007). This typical PSP profile is also present in glial cells. Progressive 
supranuclear palsy (PSP) is the second most frequent cause of degenerative 
parkinsonism. In addition to parkinsonism, the clinical symptoms include early 
postural instability, supranuclear gaze palsy, and cognitive decline. It is typically a 
sporadic disorder with peak onset at age 63 and no reported cases before the age 
of 40. 
 
1.4 Corticobasal Degeneration 
 
Corticobasal Degeneration is another 4R tauopathy that shows as clinic-
pathological feature asymmetrical atrophy in the posterior frontal and parietal lobes, 
with great neuronal loss in the substantia nigra. The minimal pathologic diagnostic 
features of CBD are cortical and striatal tau-positive neuronal and glial lesions, 
especially astrocytic plaques (Feany and Dickson, 1995). Small NFTs and 
corticobasal bodies can also be seen, and ultrastructural examination revealed that 
are made prevalently of 24 nm diameter twisted ribbons, but tubular structures and 
amorphous profile are seen in astrocytes, and twisted tubules in oligodendroglial 
cells (Arima, 2006). The age of onset of CBD is typically late adulthood, commonly 
set between the fifth to seventh decades of life. CBD, as PSP, is associated with a 
higher frequency of the MAPT H1 haplotype. The clinical presentation of CBD is a 
progressive asymmetric movement disorder with symptoms initially affecting one 
limb, including various combinations of akinesia and extreme rigidity, dystonia, focal 
myoclonus, ideomotor apraxia, and alien limb phenomena, with also a mild 
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cognitive impairment. 
 
1.5  Argyrophilic Grain Disease 
 
Argyrophilic Grain Disease (AGD) is a 4R tauopathy with grains positive to Gallyas 
staining (but not to all the silver impregnation methods) found mainly in dendrites 
and dendritic branches and some axons as the main hallmark of pathology (Tolnay 
and Clavaguera, 2004). Other non-specific lesions include: pre-tangle neurons, 
coiled bodies, tau-immunoreactive astrocytes, swollen neurons, NFTs and neuropil 
threads. Grains are small (4-8 nm diameter) round and spindle-shaped. 
Ultrastructurally, grains contain straight filaments of 10-20 nm diameter and tubular 
structures of 25 nm diameter. 
 
1.6  Globular Glial Tauopathies 
 
Globular Glial Tauopathies (GGT) are 4-repeat tauopathies characterized by tau-
positive, globular glial inclusions, including both globular oligodendroglial inclusions 
and globular astrocytic inclusions. The brain shows atrophy of the frontal and 
temporal lobes. This is associated with argyrophilic (Gallyas) and 4R-tau 
oligodendroglial and non-argyrophilic 4R-tau immunoreactive globular astroglial 
inclusions, together termed globular glial inclusions, a feature that can help to 
discriminate GGT from PSP, with which shares a common astrocytic inclusions 
morphology (Ahmed et al., 2013). Recently some mutations in the MAPT locus 
have been found to cause a pathologic phenotype typical of GGT, even if it shows 
to be prevalently sporadic (Tacik et al., 2015). From a neuropathological point of 
view, it can be classified in different subtypes thanks to its wide pathological 
heterogeneity deriving from the different spread of the tau-positive inclusions, but if 
these subgroups fall under a pathological spectrum of the same disease entity or 
are to be considered distinct pathologies is still a matter of debate. 
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1.7  Alzheimer's Disease 
 
Alzheimer's Disease (AD) is a chronic neurodegenerative disease with well-defined 
pathophysiological mechanisms, mostly affecting medial temporal lobe and 
associative neocortical structures. Neuritic plaques and NFTs represent the 
pathological hallmark of AD, and are respectively related to the accumulation of the 
amyloid-beta peptide (Aβ) in brain tissues, and to cytoskeletal changes that arise 
from the hyperphosphorylation of tau protein in neurons. According to the amyloid 
hypothesis of AD; the overproduction of Aβ is a consequence of the disruption of 
homeostatic processes that regulates the cleavage of the amyloid precursor 
protein (APP), a transmembrane integral glycoprotein of 110-130kDa. In the human 
brain there are different amyloid-beta species, but the most prevalent are the ones 
made of 40 and of 42 amino acids. This protein is metabolized by two distinct 
pathways, the secretory pathway (non amyloidogenic) and the amylodogenic 
pathway. The last is the one that give rise to the most toxic Aβ species, because 
APP is alternatively cleaved by β-secretase, releasing a smaller terminal N-
fragment (sAPPβ) and a longer C-terminal fragment (C99) that contains the full 
amyloidogenic amino acid sequence. A further cleavage by γ-secretase yields the 
amyloid-beta peptides (Aβ), which are released as monomers that tend to 
aggregate progressively into dimers, trimers, oligomers, protofibrils and fibrils, to 
finally deposit and originate the amyloid plaques. Despite their similarities, Aβ42 is 
more prone to aggregation and fibrillization.  Aβ oligomers are considered the most 
toxic form of the amyloid derivates. They interact with neurons and glial cells 
leading to the activation of pro-inflammatory cascades, mitochondrial dysfunction 
and increased oxidative stress, impairment of intracellular signaling pathways and 
synaptic plasticity, increased tau phosphorylation and induction of neuronal 
apoptosis and cell death (Recuero et al., 2004). These mechanisms altogether give 
rise to a self-perpetuating, positive feedback loop in which the production of Aβ 
peptides leads to deleterious events to the neuronal cells, which in turn leads to 
dysfunction of APP metabolism and more production of Aβ peptides. 
As said before, the other neuropathological hallmark of AD is the presence of 
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intraneuronal lesions called neurofibrillary tangles. The main components of NFTs 
are the paired helicoidal filaments (PHFs) of 10 nm diameter with a helical period 
of 160nm, which are mainly constituted of hyperphosphorylated tau. 
Hyperphosphorylation of tau may be the initial step in the physiopathology of AD; 
other pathological events including abnormal APP cleavage may be secondary 
(Rhein and Eckert, 2007). Nevertheless, the lack of mutations in the MAPT gene 
associated to early or late onset AD weaken the hypothesis that tau pathology is 
the earliest event in AD (Oide et al., 2006). Therefore, other hypothesis regarding 
the initial steps of AD pathology have been proposed, involving the activity of 
proteins and enzymes that play their role upstream in the cascades involved in the 
regulation of the APP/Aβ and tau metabolism, such as GSK3β, which plays a 
pivotal role in the regulation of tau phosphorylation, leading to its 
hyperphosphorylation when over activated (Lovestone et al., 1994). 
Clinically, AD is defined by a gradual loss of memory and other cognitive functions, 
and the symptoms caused became more and more severe with the progression of 
the pathology. We can distinguish 4 stages: the preclinical stage, characterized by 
mild cognitive impairment, inability to plan and alteration in behavior; the mild 
dementia stage, characterized by learning impairment and spatial disorientation; 
the moderate dementia stage, with severe impairment of recent memory and 
language capacity; the severe dementia stage, in which almost all the cognitive 
functions are lost (Förstl et al.,1999). 
Familial forms of AD have an incidence estimated from 5-10% to 50% and they are 
characterized by the presence of mutations and polymorphisms in some genes 
which encode for proteins implicated in early or in late onset of illness, like APP, 
ApoE, Presenilin 1 and 2, and many others whose inheriting rises the probability to 
develop AD (Karch et al., 2014). 
 
2. Tau 
2.1 Gene and protein 
 
A protein factor involved in microtubule assembly was firstly isolated from porcine 
brain in 1975 and named tau (Weingarten et al., 1975). This protein was 
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recognized to be the same ~50 kDa microtubule-associated protein isolated from 
PHFs extracted from AD brains one year before, with the exception that the former 
was abnormally phosphorylated (Iqbal, 1974). Only in 1988 the MAPT gene 
encoding tau protein was cloned after the screening of cDNA libraries prepared 
from the frontal cortex of an AD patient (Goedert et al., 1988).Six tau isoforms 
deriving from differential mRNA splicing were discovered to be characteristically 
expressed during human brain development (Goedert et al., 1989).The proteins 
varies from 352 to 441 amino acids in length, and they differ from each other for 
the presence or absence at the N-terminus of an insert of 29-amino or 58-amino 
acids, and for 31 amino-repeat at the C-terminus (fig.1).The latter depends on the 
differential splicing of exon 10, which give rise to three tau isoforms with four 
repeats (4R), or to three tau isoforms with three repeats  (3R). The repeats with 
some adjoining sequences constitute the microtubule-binding domains of tau, each 
encoded by exon 9, 10, 11 and 12(Hutton et al., 1998). The four motifs are copies 
of an 18 amino acids sequence that comprise a repeat, and each repeat is 
separated by a 13-14 amino acid inter repeat sequence (Lee et al., 1988).   
The human MAPT gene was discovered to be located on chromosome 17q21-22 
(Donlon et al., 1987), and is over 50kb in size, with two different haplotypes, H1 
and H2, and contains 16 exons. The H2 haplotype differs from H1 by the deletion 
of a 238bp sequence upstream of tau exon 10. As said before, another feature of 
the H2 haplotype is the presence of an inverted sequence of 900kb. Compared 
with H2, the H1 haplotype is relatively heterogeneous. A total of 24 SNPs in the 
MAPT gene vary in the background of the H1 haplotype, and enables classification 
of the H1 into sub-variants that are sometimes associated with increasing risks of 
developing certain neurodegenerative diseases (Pittman et al., 2004). 
The transcription factors AP2 and SP1 bind to tau core promoter region upstream 
exon 1 and are necessary for promoter activity (Heicklen-Klein et al., 2000; Gao et 
al., 2005). 
Tau protein has hydrophilic properties and exist normally as natively unfolded or 
intrinsically disordered protein (Jeganathan et al.,2008). The polypeptide chain of 
tau is highly flexible and mobile and has a low content in secondary structures. Tau 
protein contains three major domains: an acidic N-terminal part; a proline-rich 
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region and a basic C-terminal domain. Thus, tau protein is a dipole with two 
domains having opposite charge (Sergeant et al.,2008). This asymmetry is 
important for interactions between tau and microtubules and other partners as well 
for internal folding and aggregation. 
The C-terminal portion binds to microtubules, promotes their assembly and is 
called “assembly domain” (Steiner et al.,1990). 
The middle region of tau (150-240aa), termed “proline-rich domain” (Mandelkow et 
al., 2012) contains the PPXXP/PXXP motifs, which are targets of many proline-
directed kinases and binding sites for proteins with SH3 domains, and the KKKK 
sequence involved in heparin binding (Avila et al., 2004). The acidic part of tau 
does not bind to microtubules but project away from the microtubule surface and is 
termed “projection domain” (Hirokawa et al., 1988). This domain may interact with 
other cytoskeletal elements, mitochondria or neuronal plasma membrane (Jung et 
al., 1993; Brandt et al., 1995; Al Bassam et al., 2002). 
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Fig. 1. MAPT gene and Tau splicing isoforms. The MAPT gene encodes for the 
tau protein. The protein includes 16 exons. The difference between the isoforms is 
given by the presence or absence of a 29 amino acids insert or of a 58 amino acids 
insert at the N-terminal, and by the number of repeats in the microtubule-binding 
domain, which vary between three and four. 
(Image courtesy from Bukar Maina et al., (2016) “Nuclear Tau and its potential role in Alzheimer's disease” 
Biomolecules, 6(1),9) 
 
 
2.2 Physiological role 
 
Tau is a multifunctional protein, with numerous binding partners. Its main function is 
to bind and stabilize microtubule (MT), as was firstly observed (Weingarten et al., 
1975), thus it is considered to be a microtubule associated protein (MAP). The 
regulation of microtubule dynamic instability is due to its capability in regulating 
tubulin polymerization (Trinczek et al., 1995). The tubulin binding site is located at 
the C-terminal of tau, which is highly acidic, and can be regulated by tau post 
translational modifications, such as phosphorylation. Phosphorylation may alter the 
protein positive charge thus leading to a change in conformation and in 
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detachment from microtubules (Fisher et al., 2009). Tau may interact with 
microtubules directly or indirectly. Direct interaction includes the binding, 
stabilization and assembly. NMR analysis detect specific sequences involved in MT 
binding (Mukrash et al., 2007). These sequences include 240KSRLQTAPV248, 
275VQINKKLDLS285, and 297IKHV300, the latter both coded by exon 10, and this can 
explain why the 4R isoforms binds more strongly to microtubules than the 3R 
isoforms (Panda et al., 2003). 
Binding of tau to microtubules can take part in axonal transport and can interfere 
with binding of motor proteins. A gradient of tau along the axon with the highest 
level around the synapse might facilitate the detachment of motor proteins from 
their cargo near the presynaptic terminal and might increase axonal transport 
efficiency (Dixit et al., 2008). 
Tau can also bind spectrin and actin filaments (He et al., 2009), and this might 
allow tau-stabilized microtubules to interconnect with neurofilaments that restrict 
the flexibility of the microtubule (Kolarova et al., 2012). 
Tau can also act as a postsynaptic scaffolding protein. As a scaffold protein, tau 
modulates the activity of Src tyrosine kinases, c-Src and Fyn, and facilitates c-Src-
mediated actin rearrangements (Sharma et al., 2007). In the case of Fyn, it has 
been suggested that tau normally tethers Fyn to PSD-95/NMDA receptor signaling 
complex (Ittner et al., 2010). Tau can also act as a scaffold protein in 
oligodendrocytes, where it my connect Fyn and microtubules in order to enable 
processes extension (Klein et al., 2002). 
Another function of tau is involvement in growth factor signaling (Niewiadomska et 
al., 2005; Niewiadomska et al., 2006). Under NGF stimulation, tau is distributed at 
the ends of cellular extensions, where it associates with actin in a microtubule-
independent manner (Yu et al., 2006). Tau facilitates signaling through receptors 
for NGF and EGF, that may increase the activity of the mitogen-activated protein 
kinase (MAPK). 
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2.3 Post translational modifications 
 
Several modifications have been described for tau protein. It is subjected to 
modifications by serine, threonine and tyrosine phosphorylation, isomerization, 
glycation, nitration, O-GlcNAcylation, acetylation, oxidation, polyamination, 
sumoylation, ubiquitination, and proteolytic cleavage (truncation). 
 
Phosphorylation 
Phosphorylation is the main post-translational modifications affecting tau that it's 
been described. Almost 85 phosphorylation sites have been identified in tau 
molecule. Kinases that are involved in tau phosphorylation can be divided into 
three classes: proline directed protein kinases (PDPK), non-PDPK protein kinases 
and tyrosine protein kinases (TPK). 
 
 GSK-3 
Glycogen synthase-3 (GSK-3), belongs to the PDPK class, and is a 
serine/threonine-specific kinase whose activity is regulated by phosphorylation. 42 
GSK-3 phosphorylatable sites on tau have been identified. The level of GSK-3 
increase in neurodegeneration (Pei et al., 1997), and its activity correlates with the 
increasing amount of NFTs (Leroy et al., 1992), where it is found (Yamaguchi et al., 
1996). The GSK-3β isoform preferentially phosphorylates Ser/Thr residues 
followed by a proline (Ser/Thr-prolin motif). The most favorable phosphorylation 
sites of GSK-3β are Ser396/Ser404 in the C region of tau (Liu et al., 2006). It is 
also been observed that tau phosphorylation by GSK-3β only at the C-region 
increased its activity of stimulating MT assembly (Liu et al., 2007). GSK-3β also 
phosphorylates tau at Thr231, one of the most prominent sites for the regulation of 
its activity at early stages. The modification at this epitope causes a conformational 
change in the protein affecting its ability to bind to MTs, and it is considered to be 
an early event in the progression of AD (Daly et al., 2000). 
 
 Cdk5 
Cyclin-dependent kinase 5 (cdk5) is a serine/threonine kinase which belongs to the 
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PDPK class. Its activity is regulated by phosphorylation, and by the binding of an 
activator subunit, p35 or p25 which is generated by calpain-dependent proteolytic 
cleavage of p35 (Lee et al., 2000). The p25/cdk5 holoenzyme phosphorylates tau 
and reduces its ability to bind to microtubules, it alters cell morphology, causes 
cytoskeletal disruption and apoptotic cell death (Patrick et al., 1999). It 
phosphorylates tau on Ser202, Ser205, Thr212, Thr217, Thr235, Ser396 and 
Ser404, as it appears in AD brains. 
 
 CK1 
Casein Kinase 1 (CK1) is a family of protein kinase non-PDPK. It can 
phosphorylate tau at Ser202/205 and Ser396/404 in vitro and in cell culture, 
modulating its binding affinity for microtubules (Li et al., 2004). 
 
 Dyrk1A 
Dyrk1A, a non-PDPK kinase, phosphorylates tau mainly at Thr181, Ser199, 
Ser202, Ser205, Thr212, Thr217, Thr231, Ser396, Ser400, Ser404 and Ser422, all 
Ser/Thr phosphorylation epitopes belonging to the P region. Phosphorylation by 
Dyrk1A inhibits tau capability of microtubule assembly and increases its ability to 
self-aggregate (Ferrer et al., 2005). 
 
 PKA 
Cyclic AMP (cAMP)-dependent protein kinase (PKA) is a serine/threonine protein 
kinase which belongs to the non-PDPK class. PKA catalyzes tau phosphorylation 
and triggers the kinase activity of GSK-3β at several AD-relevant phosphorylation 
sites, including Ser214, Ser262 and Ser409, which span over the P-region, the MT 
binding repeats and the C-region of tau, decreasing MT assembly (Liu et al., 2007). 
 
 CaMKII 
CaMKII regulates important neuronal functions including neurotransmitter 
synthesis and release, modulation of ion channel activity, synaptic plasticity and 
gene expression. It phosphorylates tau at Ser262, Ser356, Ser409 and Ser416, 
and these sites are phosphorylated in brains of AD patients (Steiner et al., 1990). 
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 Phosphatases 
Protein phosphatases (PPs) responsible for dephosphorylation of tau include: 
PP2B, PP2A, PP1 and PP5. PP2B is one of the main serine/threonine 
phosphatases in the brain; its activity depends on Ca2+/calmodulin, and is 
associated with microfilaments and MTs development. PP2A is localized on MTs 
and binds tau directly. PP5 is associated with MTs and dephosphorylates tau in 
neuronal cytoplasm. The inhibition or the absence of this phosphatase in the cells 
causes the hyperphosphorylation of tau protein suggesting a possible role of this 
protein in AD development (Pevalova et al., 2006). 
 
 Critical phosphorylation sites 
Many epitopes can be considered involved in tau aberrant activity in AD and in 
other tauopathies. AT8 epitope (Ser199/Ser202/Ser205) is considered an early 
hallmark of AD and other tauopathies. The hyperphosphorylation of these three 
residues can cause MTs instability, diminished mitochondria axonal transport and 
neuronal cell death (Alonso et al., 2010; Shahpasand et al., 2012). The same effect 
is due to the hyperphosphorylation of residues Thr212/Thr231/Thr262.Kinetic 
studies also confirmed that the AT8 epitope, Thr212, Thr231/Thr235, 
Ser262/Ser356, and Ser422 are among the critical phosphorylation sites that 
convert tau into pathological molecule prone to aggregation. Phosphorylation at 
Ser262/Ser356 its also been reported to inhibit MTs assembly (Biernat et al., 1993; 
1999). Phosphorylation of Ser396/Ser404 by GSK-3β increases tau activity of 
stimulating MTs assembly (Liu et al., 2007). 
Pseudo phosphorylation of Ser422 has shown an increase in aggregation and a 
reduced cleavage at Asp421 (Guillozert-Bongarts et al., 2006). 
 
Glycosylation 
Glycosylation is the attachment of oligosaccharides to a protein. There are two 
types of glycosylation: N-glycosylation and O-glycosylation. The first derives from 
the attachment of a sugar on the amine radical of asparagine, while the second 
from the attachment of a sugar on the hydroxyl radical of serine or threonine. 
Protein tau can be O-GlcNAcylated in vitro in recombinant systems and in some 
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transfected cell-lines in culture (Smett-Nocca et al., 2011). In vivo it has been 
shown to reduce tau phosphorylation in rat cortex and hippocampus (Yuzwa et al., 
2008). 
 
Glycation 
Tau glycation seems to prevent its degradation and to promote its accumulation 
(Edesma et al., 1996). It triggers the production of free radicals amplifying oxidative 
stress, which in turn increases tau phosphorylation (Su et al., 2010). By this 
mechanism, tau can be oxidized at C322, leading to PHF assembly (Landino et al., 
2004). Oxidative stress promotes tau nitration which indicates that tau glycation 
can indirectly induce both tau oxidation and nitration, leading to tau 
phosphorylation and oligomerization (Zhang et al., 2006). 
 
 
Acetylation 
After phosphorylation, acetylation is one of the major post-translational modification 
to which tau undergoes. Lysine acetylation in particular it is been observed to 
neutralize charges in the MT binding domain interfering with tau capability to bind 
MTs. Acetylation of Lys280 increases cytosolic tau fraction and it's correlated with 
tau hyperphosphorylation. Acetylated Lys280 is present in intracellular NFTs and it 
precedes tau truncation (Cohen et al., 2011; Irwin et al., 2012). 
 
Polyamination 
The reaction of polyamination by transglutaminase (TGs) involves a glutamine (Q) 
as acyl donor and a lysine (K) as acyl acceptor. Eight acceptor sites and ten donor 
sites were identified on tau protein (Murthy et al., 2008). Polyamination is observed 
on the protein before NFTs formation (Singer et al., 2002). 
 
Ubiquitination 
Tau has been shown in non-pathological conditions to be ubiquitinated and 
proteolytically processed by UPS (Ubiquitin-proteasome-system) (Liu et al., 2009). 
Tau ubiquitination can occur in PHFs after its hyperphosphorylation and 
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glycosylation, and increases as PHFs maturate (Bancher et al., 1991; Iqbal et al., 
1998). 
 
Nitration 
Nitration is the addiction of nitrogen dioxide on tyrosine of an organic molecule. It 
occurs at 4 sites, and it is been suggested to be involved in tau aggregation 
(Horiguchi et al., 2003). Nitration was also proposed to impair tau ability to promote 
tubulin assembly (Reynolds et al., 2006), leading to tau oligomerization (Zhang et 
al., 2005). 
 
2.4 Tau cleavage 
 
Tau protein truncation occurs in AD brains at D421, E391, D13 residues, and 
enhances the capability of the protein to aggregate and cause neuronal apoptosis 
(Chung et al., 2001). These truncated forms are especially found in PHFs (Mena et 
al., 1996), and this suggest that they can contribute to protein aggregation in AD.  
Tau phosphorylation at Ser422 seems to protect tau from being cleaved at Asp421 
by caspase-3, hence dephosphorylation of this epitope is required for its proteolytic 
processing (Guillozet-Bongaarts et al., 2007). 
Tau cleavage can be achieved by calpains, and especially calpain-2 that co-
localize with tau filaments in AD and in frontotemporal dementia (Adamec et al., 
2002, Corset et al., 2008). 
 
2.5 Tau aggregation 
 
Tau aggregates display different morphologies in different tauopathies. The type of 
aggregate formed is determined by the tau isoform involved or in the mutations in 
the MAPT gene (Crowther et al., 2000). Tau appears to be highly phosphorylated 
and is more susceptible to aggregate than non-phosphorylated tau (Avila et al., 
2004). The increased pool of soluble tau undergoes others conformational changes 
which may support initial steps of tau assembly into filaments (Hyman et al., 2010). 
Physiological and pathological tau species include: monomers, dimers/trimers, 
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small soluble oligomers, insoluble granular tau oligomers, filaments, pretangles, 
large non-fibrillary tau aggregates, neurofibrillary tangles and ghost tangles 
(Cowan et al., 2013; Brunden et al., 2008). Tau oligomers are considered the most 
toxic among the tau species, and that fibrillary tau is considered neither necessary 
nor sufficient for tau-induced toxicity, and may even represent a neuroprotective 
strategy (Spires-Jones et al., 2011). According to some studies, the first abnormal 
event in AD is the formation of the PHF-tau minimal core unit comprising tau 
truncated at Glu-391. A series of phosphorylation events along the N-terminal 
(Luna-Munoz et al., 2007; Mena and Luna-Munoz, 2009) would favor the action of 
caspase-3 that cleaves tau at Asp421 (Gamblin et al., 2003). This cause a 
sequential cycles of events in which truncated tau captures full length tau, which 
undergoes a cleavage and became able to bind further full length molecules with 
increased avidity (Wischik et al., 1996) generating oligomeric aggregates that can 
develop to neurofibrillary tangles (fig.2). 
Tau has long stretches of positively and negatively charged region which don't 
allow intermolecular hydrophobic association. Two hexapeptides, 275VQJINK280 and 
306VQJVYK311 which are respectively located at the beginning of the second and 
third MBDs are prominent in generating β-sheets structures during tau aggregation 
process (Von Bergen et al., 2000; Fisher et al., 2009). Self-aggregation is inhibited 
by the presence of intact N- and C-terminal domains, but when these ones are 
aberrantly phosphorylated or cleaved, the conformational structure changes 
exposing the sticky repeat regions which leads to the formation of PHFs (Alonso et 
al., 2001). 
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Fig 2. Sequence of stages leading to tau aggregation in NFTs. Detachment of 
tau from microtubules increases amount of misfolded tau monomers. Monomers 
aggregate into small soluble tau oligomers (GTOs). Probably both, small oligomers 
and GTOs form paired-helical filaments (PHFs) but GTOs are considered to be the 
main precursor of PHFs. Subsequently PHFs spontaneously aggregate into 
neurofibrillary tangles (NFTs). 
(Image courtesy from Mietelska-Porowska et al., 2014 “Tau protein Modifications and Interactions: Their role 
in function and dysfunction” Int.J.Mol.Sci. 15). 
 
2.6 Secretion 
 
Tau can be directly involved in the spreading of AD and other tauopathies to 
neighboring neurons. Tau pathology can be induced and propagated by the 
injection of tau oligomers into wild type or mutated MAPT transgenic mice (Iba et 
al., 2013) and exogenous tau aggregates can be transferred from cell to cell in vitro 
(Iba et al., 2013; Frost et al., 2009) and in vivo (De Calignon et al., 2012 ; Liu et al., 
2012). In the case of soluble monomeric or oligomeric tau, the exocytosis 
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appeared to be clathrin-dependent (Rubinzstein et al., 2006), while other tau 
aggregates could bind heparin in the extracellular matrix and be internalized by 
macropinocytosis (Holmes et al., 2014). It is also been observed that tau spreading 
could follow a non-conventional secretory pathway led by the RER and Golgi. 
COPII vesicles budding from the ER containing tau at their surface can fuse 
directly with the plasma membrane for secretion (Nickel et al., 2009). Another 
hypothesis is that tau secretion could occur through non-COPII-coated vesicles 
forming at the ER or vesicles forming at the Golgi with tau attached to surface 
(Ponnanbalam et al., 2003). Another study reported that hyperphosphorylation and 
cleavage at Asp421 increased tau secretion, at least in Hela cells (Plouffe et al., 
2012), starting a vicious cycle that led to the amplification of secretion. 
Hyperphosphorylation would enhance the secretion trough microvesicles or the 
other non-conventional pathways mentioned before. Dephosphorylation would 
occur in the extracellular space and dephosphorylated tau would activate the 
muscarinic receptors, inducing an increase of intracellular calcium, an event linked 
to the increase of tau hyperphosphorylation. 
 
 
2.7 Mutations 
 
53 MAPT mutations have been identified, and they can be classified on the basis 
of their position on the gene. Mutations affect tau at mRNA splicing level and at 
protein level. The majority of mutations affect the coding region, comprising 
missense mutations, silent mutations and deletions. Many mutations are located 
close to the splice-donor site of the introns downstream exon 9 and 10. Most 
coding region mutations are located in the MT-binding region (exons 9-12) of tau or 
close to it (exon 13). Mutations affecting exon 1, 9, 12 and 13 affect all tau 
isoforms, while mutations in exon 10 affect only 4R isoforms. The primary effect of 
intronic mutations and of some mutations affecting splicing regulatory elements is 
exerted at the level of RNA splicing, thus leading to altered expression of tau 
isoforms, in particular altering the ratio between the 3R and the 4R isoforms in the 
case of mutations affecting exon 10. Mutations can also be classified on the basis 
28 
 
of their molecular effect on tau-MTs interaction and/or fibril formation. Some 
mutations however share the same effects (Hutton et al., 1998; Spillantini et al., 
1998). 
 
Mutations altering the tau-MTs interaction and fibril formation 
 
Being located in the MBD, most missense mutations can cause an alteration in the 
binding of tau protein to MTs. Most of these mutations are located in exon 9, 11, 12 
and 13, with the exception of P301L and P301S which are in exon 10 and share 
the same feature and, excepting Q336R/H, located in exon 12 that is been 
observed to enhance tau binding affinity to MTs, as will be discussed further. Also 
some mutations located outside the MBD can have an effect on binding affinity, as 
it is has been observed for mutations located on exon 1. Other mutations can have 
pre-fibrillogenic effects, as it has been observed in vitro on heparin-induced tau 
filament assembly (Goedert et al., 1996). 
 
Mutations altering tau RNA splicing 
 
All intronic mutations and a few coding-region mutations affect the splicing of exon 
10 altering the ratio between the 4R and the 3R isoforms, in most cases increasing 
the 4R isoform. The majority of intronic mutations are located in the intron following 
exon 10, with only two mutations described in the intron following exon 9. Missense 
mutations affecting splicing of exon 10 are N279K, G303V and S305N, and silent 
mutations are L284L, N296N and S305S (Gasparini et al., 2007). 
 
Mutations altering Tau-MTs interaction, fibril formation and RNA splicing  
 
Several missense mutations exert their effects at both protein and RNA levels. 
ΔK280, ΔN296 and N296H mutations greatly reduce the ability of tau to bind to 
MTs and to promote MTs assembly in vitro. The opposite effect it has been 
observed for Q336R/H and S305N mutations. Effects at the mRNA level also have 
been demonstrated for these mutations, and they increase the splicing-in of exon 
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10, while others leave it unaltered and the ΔK280 decreases it. 
 
 
3. Q336H and ΔK280 
3.1 Q336H 
 
Q336H is a missense mutation located in the coding region of exon 12. It has been 
observed in one patient with an inherited form of dementia with features typical of 
Pick disease. This patient shared a common patho-mechanism with a previously 
reported case variant affecting the same codon, Q336R (Pickering-Brown et al., 
2004). Sarkosyl-insoluble tau isoforms extracted from samples of brain tissue 
displayed a high prevalence of 3R isoforms, as expected from a Pick Disease 
phenotype. Study in vitro on the effect of the mutation on tubulin polymerization 
found out that Q336H in the 3R0N tau isoform promoted MTs polymerization at a 
rate greater than in the WT 3R0N tau. The same result was obtained about the 
promotion of tau filament formation, infact Q336H highly promotes tau 
polymerization more in the 3R isoform rather than the 4R isoform (Tacik et al., 
2015). 
 
3.2 ΔK280 
 
This is a coding mutation affecting exon 10 only in 4R tau isoforms, because it is in 
the exon 10 “linker region” between two microtubule binding repeats, which isn't 
present in the 3R isoforms, and which contains the following amino acids, 
274KVQIINKKLD287. The deletion removes either the second or the last lysine 
residue at position 280 or 281, and by the use of microtubule assembly assays it 
has been shown that the mutation induced a strong decrease in microtubule 
binding affinity than the wild type protein (Goode and Feinstein 1994; Trinczek et 
al., 1995). It is a mutation that affects transcript tau and tau protein, affecting 
splicing of exon 10 inhibiting its inclusion, and diminishing tau ability to promote 
microtubule assembly in vitro (Rizzu et al., 1999). A study conducted on cell culture 
has shown that ΔK280 decreased the ability of tau to regulate the percentage of 
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time microtubule spent growing, shortening and attenuated, showing a massive 
effect on the regulation of the growth rate compared to 4R wild type tau, while not 
altering the effect on the shortening rate (Bunker et al., 2006). It is also been 
observed that ΔK280 strongly promotes the aggregation of tau into paired-helical 
filaments (PHFs), because it enhanced the propensity of the protein to form β-
structure (Barghorn et al., 2000).                                                          
 Various transgenic mouse models have been developed during the years. One of 
the most significant expressed the transgene with the full length tau 4R2N under 
the control of a TET-OFF system, and it has been observed that tangles started at 
24 months of age, although it was also present a great pre-tangle pathology, 
including hyperphosphorylation at specific epitopes (262, 356), and conformational 
changes that enhance the propensity to aggregate (Eckerman et al., 2007). 
Another mouse model used as transgene a fragment from 244 to 272, comprising 
the four microtubule binding domains. In this model tangles formation started early 
from 2-3 months of age, with great neuronal loss in the hippocampus (Mocanu et 
al., 2008). 
 
4. FRET and FRAP 
4.1 FRET 
Fluorescence resonance energy transfer (FRET) is a mechanism of energy 
transfer between two light sensitive molecules. An excited fluorophore can 
deactivate by non-radiative transfer of energy from the excited dipole of the donor 
fluorophore to the dipole of the accepted one. The acceptor fluorophore in turn can 
return to its ground state by different mechanisms including photon emission, non-
radiative dissipation or again energy transfer to another acceptor molecule. In 
order for FRET to occur, there is the necessity to have an overlap of the emission 
spectrum of the donor and the excitation spectrum of the acceptor. The second 
requirement is a close proximity of donor and acceptor, ranging in a distance of 1-
10nm. In addition to a sufficient proximity of the chromophores, an appropriate 
relative orientation of the dipole vectors is necessary for a high FRET to occur. 
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Many biological processes like protein interactions take place within the spatial 
range at which FRET occurs, so it is been widely used as a tool to study molecular 
interactions. The efficiency of FRET is given by the ratio of donor excitation events 
that result in FRET, to the total number of excitation events, and is directly related 
to the distance R between the fluorophores by the power of six: E= R06/R6+ R06. 
While R describes the actual distance between fluorophores, R0 is called the 
Förster distance and describes the distance at which E is 0.5, or where exactly 
50% of the donor excitation events lead to FRET:  R0=0.2108[k2Φ0n-4J]1/6. R0 is 
different for each FRET pair, and is used as a parameter to describe the 
capabilities of this pair to produce FRET under certain conditions, so it is used as a 
criteria to select FRET pairs. Because FRET efficiency and distance of donor and 
acceptor are relatable, FRET has found many applications in the last decades, 
often to prove the interaction and the co-localization of two probes, which are 
bound to fluorophores. An important discovery in relation to FRET was the 
description of the Green Fluorescent Protein (GFP) in 1962 by Osamu Shimomura 
(Shimomura, 2009). GFP is a naturally fluorescent protein of the jellyfish species 
Aequorea victoria. After the elucidation of its DNA coding sequence and the 
possibility to express it outside Aequorea victoria, synthetic variants of the protein 
have been produced, obtaining different fluorophores that shifted the color 
emission to other wavelengths, thereby producing fluorescent proteins that span 
the entire visible spectrum from blue to red and even beyond (Olenyc et al., 2007). 
The major consequences of this discovery is the possibility to develop many donor-
acceptor pairs, and to genetically link them to a variety of spacers leading to 
intramolecular FRET. If a spacer in some way responds to a change in the 
environment, leading to an alteration in the distance between the fluorophores this 
will result in a change of the FRET signal. This kind of construct is a FRET-
biosensor, and since an unlimited variety of spacers can be designed and 
associated with a great diversity of fluorophores pairs, it is possible to use these 
biosensors for studying a lot of biological processes, and make them quantitatively 
measurable and visible. For example, it is been used in different studies of 
Alzheimer's disease, like the sensor constructed to detect Aβ oligomers using CFP 
and YFP respectively as donor and acceptor (Takahashi et al., 2012). Other 
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studies utilized FRET to detect the interaction between tau and MTs (Nouar et al., 
2013).  
Methods to measure FRET efficiency 
FRET efficiency is measured and used to identify interactions between the labeled 
complexes. There are several ways to measure FRET efficiency, by monitoring the 
changes in the fluorescence emitted by the donor or the acceptor, but the two 
mainly used are Sensitized Emission and Acceptor Photobleaching. 
Sensitized Emission 
This method measures the variation in the acceptor emission intensity (Clegg and 
Robert, 2009). When donor and acceptor are in proximity (<50Å) due to 
interactions of the two molecules, the acceptor emission will increase due to the 
intermolecular FRET from the donor to the acceptor. This method is preferentially 
used to monitor protein conformational changes, labelling the protein with a donor 
and an acceptor at two loci. When a modification of the protein conformation 
changes the donor and the acceptor distance and relative orientation, FRET 
change is observed. 
Acceptor Photobleaching 
FRET efficiency can also be inferred from the photobleaching rates of the donor in 
the presence or absence of an acceptor (Clegg and Robert, 2009). This method is 
based on the excitation of the single donor in specimen with or without the 
acceptor fluorophore and the monitoring of the donor fluorescence over time. 
Photobleaching consists in the permanent inactivation of excited fluorophores, so 
resonance energy transfer from and excited donor to an acceptor fluorophore 
prevents the photobleaching of that donor fluorophore, so a high FRET efficiency 
consist in a longer photobleaching decay time constant.  
4.2 FRAP 
Fluorescence photobleaching after recovery (FRAP), is a technique commonly used 
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to study the dynamics of fluorescent molecules in living cells (Cardullo et al.,1991; 
Mullineaux and Kirchoff 2007; Carisey et al., 2011). The technique now is routinely 
used to monitor qualitatively and quantitatively the dynamics of molecule both on 
cell surface and within the cytoplasm. FRAP is been used to measure the rate and 
extent of molecular mobility, the presence of binding interactions, and how these 
properties are affected with different treatments. These kinetics data are then 
quantified by analyzing the resulting fluorescence-intensity recovery curve versus 
time (Waters, 2007). As described previously, fluorescent molecules are generally 
susceptible to photobleaching, which result in the signal fading over time. 
Photobleaching is dramatically accelerated as the excitation light intensity 
increases; in the presence of an intense laser source, complete photobleaching can 
occur in the order of milliseconds. FRAP takes advantage of the rapid and 
irreversible photobleaching of fluorescently labeled molecules within a region of 
interest using a laser tuned to an appropriate wavelength for short duration of time 
(typically less than 20 msec). Following the light pulse, the fluorescence intensity is 
monitored in an area around and including the region of interest using a low-
intensity light source to monitor the movement of photobleached and fluorescent 
molecules over time. FRAP has two quantitative parameters: the mobile fraction 
(Mob), which is the amount of fluorescence recovered after photobleaching, and the 
recovery half time (t1/2), which is the minimum time required for the recovery of 50% 
of the fluorescence in the region of irradiation (ROI):t1/2 is inversely proportional to 
the diffusion coefficient of the fluorescent molecule which is in turn influenced by 
the dimension of the molecule and binding interactions. FRAP analyses allow to 
plot a recovery curve reflecting diffusion and binding dynamics. These recovery 
curves can be fitted by two different equations: a FRAP curve fitted by a simple 
exponential equation, representing the case in which diffusion and binding cannot 
be separated; a FRAP curve fitted by the sum of the two exponentials where there 
is an initial short diffusive phase followed by a longer binding phase (Nouar et al., 
2013). FRAP techniques is often used to obtain information about the mobility of 
proteins and about protein interactions that can influence the diffusion of molecules.  
In recent reports tau mobility has also been studied by FRAP, and the results 
showed that the FRAP curve is fitted by two exponentials, suggesting the presence 
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of a diffusive phase and a binding one (Nouar et al., 2013). The recovery curve can 
change in times of recovery or in the kind of fitting if conditions in the cell changes 
for example stabilizing or destabilizing MTs (Breuzard et al., 2013; Nouar et al., 
2013). 
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MATERIAL AND METHODS 
 
 
 
1.Site-directed mutagenesis 
 
 
The CST construct used, already present in the lab, comprise Tau-D, a 4R isoform 
which lacks of the N-terminal domains and has 383aa, CFP and YFP genes 
inserted respectively upstream and downstream the TAU gene, which sequence is 
separated from the fluorophores by a linker sequence coding the peptide RSIVT. 
The promoter for the expression of the construct is the CMV, a ubiquitous promoter 
that determines a high expression of the protein in several cell types. This CST has 
been mutagenized in single residues. The mutations induced are the Q336H 
missense mutation and the deletion ΔK280 (fig.1). To modify the residues of interest 
the Site-Directed Mutagenesis Kit Q5 (New England BioLabs) was used.  
The primers used to mutagenized the sequence of TAU were:  
Fwd 5'-AGGAGGTGGCCACGTGGAAGT-3' for Q336H; 
Rev 5'-GGTTTATGATGGATGTTGCC-3' for Q336H; 
Fwd 5'-AAGCTGGATCTTAGCAAC-3' for ΔK280; 
Rev 5'-ATTAATTATCTGCACCTTCC-3' for ΔK280. 
 
Figure 1. Mutagenized CST. The image reports the sites mutagenized of the tau sensor.  
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2.Cell cultures and transfection 
 
HeLa and immortalized hippocampal neurons HT22 cells were routinely cultured in 
Dulbecco‘s Modified Eagle‘s Medium (DMEM) low glucose (Euroclone), 
supplemented with 10% Fetal Bovine Serum (FBS), 100 U/ml Penicillin and 100 
μg/ml Streptomycin.  
Cells were plated at 60%-70% confluence on 6-well dishes (Starstedt) or on Glass 
Bottom Petri Dishes (Willko) and transfected with Effectene reagent (Quiagen) 
according to the manufacturer's instructions.  
All cell types were cultured at 37°C with 5% CO2  in a humidified atmosphere.  
 
3.In vivo fluorescence imaging 
 
All imaging experiments were performed with the TCS SL laser scanning confocal 
microscope (Leica Microsystems) equipped with high numerical aperture objective 
(HCX PL Apo oil immersion 63X, 1.4 N.A.).  
105 cells have been plated on Glass Bottom Petri Dishes (Wilko) and placed in the 
incubation chamber on the stage of the inverted microscope with controlled CO2 
(5%) and temperature (37°C).  
An Argon laser was used for the excitation of CFP (excitation wavelength 458 nm) 
and YFP fluorophores (excitation wavelength 514 nm), while a He-Ne laser was 
used for the excitation of Alexa Fluor 633 (excitation wavelength 633nm).  
 
4.Immunofluorescence 
 
Cells were seeded on Glass Bottom Petri Dishes (Wilko) and after transfection were 
fixed with cold methanol for 5 min. Soon after fixation cells were permeabilyzed with 
0.1% Triton X-100 and blocked for 30 min with the blocking solution (PBS+Tween 
0,1% + BSA 1%- fresh). Primary antibody incubation has been done in blocking 
solution for 1h or O/N. Primary antibody used was: anti α-tubulin (Sigma-Aldrich), 
1:1000, mouse. Excess antibody was eliminated by several washes with PBS 1X 
and secondary antibody incubation was performed in blocking solution for 1h. 
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Secondary antibody used was: Alexa Fluor anti mouse (Life Technologies), 1:200, 
goat. Glass Bottom Petri Dishes (Wilko) were mounted with Vectashield mounting 
media (Vector Laboratories).  
 
5.FRET and FRAP experiments 
 
For FRET experiments, the excitation and detection conditions of CFP and YFP 
fluorophores were set up. Typical parameters used for experiments are: 50% of 
458nm laser intensity for CFP excitation and 10% of 514nm laser intensity for YFP 
excitation. The scanning rate is 400Hz and the zoom varies from a 4X to an 8X with 
a line average of 4-8. For sensitized emission FRET experiments three images of 
the same field of acquisition are required: the donor image (excitation of the donor 
and emission in the donor channel), the acceptor image (excitation of the acceptor 
and emission in the acceptor channel), the FRET image (excitation of the donor and 
emission in the acceptor channel).  
Images have been acquired sequentially in order to minimize the cross talk 
between channels.  
FRET analysis was performed by using two different plugins of the ImageJ software 
called Colocalization Analyzer and PixFRET (Feige et al., 2005; Hachet-Haas et al., 
2006). The former plugin calculates the FRET index image starting from images 
acquired in the donor channel, in the acceptor channel and in the FRET channel. 
The first part of the plugin evaluates the Bleed Through Donor BT between the 
donor channel and the FRET channel, and Acceptor BT between the acceptor and 
the FRET channel. In our experimental conditions, the donor and the acceptor BT 
have a value respectively of 0.04 and 0.13. These parameters are used for the 
evaluation of the FRET index image defined as FRET 
index=IFRET−BTDonor*IDonor−BTAcceptor *IAcceptor 
The PixFRET plugin calculates a normalized FRET image and the FRET efficiency 
image. For normalized FRET images the plugin calculates the ratio between a 
FRET index images and the square root of the product between the donor and 
acceptor images: NFRET=(FRETindex/√I(donor)*I(acceptor)) *100.  
FRET efficiency has been measured by Sensitized Emission, a method based on 
the evaluation of the variation in the acceptor emission intensity. FRET change is 
38 
 
observed when the distance or the orientation of the fluorophores varies, and so the 
resonance energy transfer from the donor to the acceptor. 
In FRAP experiments images of cells expressing fluorescent proteins have been 
acquired with a scanning rate of 1000 Hz; even if this condition determines a 
reduced signal-to-noise ratio in the image, it allows faster acquisitions (656 ms for 
512*512 images and 424 ms for 256*256 images). In the pre-bleaching condition, 
10 images of a single cell have been acquired and 100-120 images after-bleaching 
to follow the recovery of the fluorescence intensity. 5 images of a circular ROI with 
an Area of 12.54um2 at the maximum laser power were acquired during bleaching 
conditions.  
The analysis of FRAP recovery curves involves both their correction for whole cell 
bleaching due to continuous irradiation and their normalization. Briefly, for the 
bleaching correction, the behavior in time of the fluorescence intensity of the whole 
cell was used to correct the recovery curve of the region of interest; this resulting 
curve was then normalized by dividing it for the mean of the fluorescence intensities 
of the ROI in the prebleach experiment.  FRAP recovery curves have been fitted by 
a two phase exponential association function (OriginLab). 
 
6.Western blot and antibodies 
 
Transfected and not transfected cells were detached from plate using Trypsin 1X 
(Euroclone), washed with PBS and pelleted. Cells extracts were prepared in lysis 
buffer supplemented with protease and phosphatase inhibitors by lysis on ice for 30 
minutes, and adding loading buffer 4x and denaturing at 100°C for 5 minutes. 
Membranes were blocked with 5% skimmed milk powder in TBS containing 0.1% 
Tween 20, and detection was carried out using specific primary antibodies. Primary 
antibodies for Western blot analyses were: TAU5 (Abcam), aa220-240, 1:1000, 
mouse; α-tubulin (Sigma-Aldrich), 1:5000, mouse; TAU46 aa404-441(Abcam), 
1:200, mouse; Phospho-tau pSer262 1:250 (Thermo Scientific), rabbit; Phospho-tau 
pSer356 1.500 (Thermo Scientific), rabbit; GAPDH (Fitzgerald), 1:15000, mouse, 
actin(Sigma-Aldritch). Secondary antibodies HRP-conjugated anti-mouse or anti-
rabbit or anti-goat were purchased by Santa Cruz Biotechnology, Inc. All the 
antibodies were diluted in 1% skimmed milk powder in TBS containing 0.1% Tween 
39 
 
20. 
The signal detection has been made using ECL (Millipore) and Super Signal 
(Thermo Scientific) and acquired by ChemiDoc (Biorad).  
 
7.Morphological analysis 
 
Images for the morphological analysis were acquired as aforementioned in point 3.  
For the quantification of morphological parameters such as the total filament length 
and the number of branching points the filament tracer option of the IMARIS 
Bitplane software has been exploited. In detail, these two parameters are deduced 
by a software plugin that, based on connectivity and fluorescence intensity, 
automatically detects and segments filamentous structures revealing information 
about the topology of filaments as the sum of the lengths of all lines and the number 
of branching points within the filament. 
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RESULTS  
 
 
1. CST-Q336H and CST-ΔK280 constructs have been generated by site-directed 
mutagenesis. 
 
 
The plasmid containing the CST sequence has been subjected to site-directed 
mutagenesis. In order to isolate CST-Q336H and CST-ΔK280 mutated sequences, 
Dh5α cells have been transformed and plated on LB plates added with kanamycin.  
Twenty colonies have been picked and inoculated in LB medium. Each colony has 
been subjected to DNA extraction, and in order to screen positive colonies 
containing the CST-ΔK280 plasmid, a double digestion with restriction enzymes 
SacI and AgeI has been performed. The double digestion is expected to produce 
two DNA fragments of 4000kb and 2000kb (fig.1a; fig.1b). The same analysis has 
been performed for CST-Q336H mutant clones (data not show). 
 
 
 
Figure 1a. Screening of positive clones carrying the ΔK280 mutation.  
Candidate positive clones are: 7,13,14,16,18. Selected clones for subsequent analysis are indicated by 
black arrows. 
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Figure 1b. CST vector map with SacI and AgeI sites.  
 
Selected mutant clones have been subjected to DNA sequencing. The DNA 
sequences were analyzed with Snap Gene Viewer™ and Clustal Omega, to confirm 
the occurrence of the desired mutation. At the end of the screening one positive 
clone per each mutant has been selected. 
 
2.CST-Q336H and CST- ΔK280 mutants binds to microtubules in living cells. 
 
Hela cells have been transfected with the CST or CST-Q336H, CST-ΔK280 
plasmid. After 24-48h, the expression of the exogenous proteins has been detected 
by live imaging at the confocal microscope. In order to perform a colocalization 
experiment with the CST and the microtubule network cells have been fixed and 
immunostained with anti α-tubulin antibodies and with a fluorescent secondary 
antibody emitting in the red channel. The sequential signal acquisition in the donor, 
acceptor and red channels, revealed that mutated CST (CST-Q336H and CST- 
ΔK280) colocalizes with tubulin (fig.2), indicating that they are able to interact with 
microtubules (MTs) as the CST. 
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Fig.2. Expression of the CST in HeLa cells. Fluorescence signal of the CST (a) in the donor channel 
(blue), in the acceptor channel (yellow) and fluorescence signal of tubulin hybridized with anti α-tubulin 
antibody (red). Fluorescence signal of CST-Q336H (b), and CST- ΔK280 (c) in the donor channel (blue), 
in the acceptor channel (yellow) and of tubulin hybridized with the antibody anti α-tubulin (red). 
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3.CST-Q336H and CST-ΔK280 display different FRET signal efficiency compared to CST. 
 
In order to analyze the changes in the protein conformation caused by the two 
mutation, HeLa cells expressing CST or CST-Q336H and CST-ΔK280 have been 
used to perform FRET experiments using the confocal microscope (fig.3). 
 
     
Figure 3. FRET detection in cell expressing CST and mutated sensors.  Images of (a) CST, (b) 
CST-Q336H, (c) CST- ΔK280 acquired in the donor channel (blue), in the acceptor channel (yellow) and 
FRET channel. FRET index intensity is represented by a pseudocolor panel from dark blue to white 
indicating respectively the absence of FRET and the higher FRET. 
 
The quantification and normalization of FRET values measured on fluorescent MTs 
have been performed employing the pixFRET plug in of the ImageJ software. 
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Normalized FRET values (NFRET) obtained for both mutated CST have been 
compared to the FRET efficiency of CST and reported in fig.4. FRET efficiency of 
CST was of 22.6, while CST-Q336H showed an increase in FRET efficiency 
(28.04). The CST-ΔK280 showed a significantly lower value (8.5), that cannot be 
considered a positive FRET signal at all. The increased FRET efficiency in the CST-
Q336H suggest that the mutation induces a conformational change of Tau protein 
that reduces the distance between the donor and acceptor fluorophores, meaning 
that the N-terminal and the C-terminal are in closer contact than in wt Tau.  
On the contrary, the very low FRET efficiency value obtained for CST-ΔK280 
suggests an increase in the distance between CFP and YFP probably due to a 
more opened conformation of mutated Tau. 
 
Figure 4. FRET analysis of wt and mutated CST sensors in living cells. The box plot reports 
normalized FRET values measured on fluorescent MTs in HeLa reporter cells. ANOVA One Way has 
been performed with a p-value threshold of 0.05. CST values are significantly different from CST-
Q336H with a p-value of 0.00969, and from CST- ΔK280 with a p-value of 1.43835E-6. CST-Q336H 
and CST- ΔK280 differ significantly from each other with a p-value of 1.38779E-11.  
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4.CST- ΔK280, but not CST-Q336H mutation induced Tau protein cleavage in HeLa cells. 
 
In order to study the role of Q336H and ΔK280 mutations in the context of CST, 
total protein extracts from cells expressing mutated CST have been analyzed by 
Western blot. For this analysis also the CST-AT8mut sample, carrying the 
S199A/S202A/T205A mutation that abolish phosphorylation at the AT8 epitope, has 
been included. Western blot results showed the CST full length at the expected 
molecular weight of 110kDa by hybridization with specific anti-Tau5, anti-Tau13 and 
anti-Tau46 antibodies which respectively recognize the central Tau portion, the 2-18 
epitope and the 404-440 epitope of the longest tau isoform (fig.5). Other bands 
recognized at lower MW were detected represent CST fragments due to tau 
processing. 
The fragment at 75kDa specifically detected by anti-Tau13 and anti-Tau46 
antibodies is the result of a cleavage around the 404-440 epitopes, probably at the 
Asp421 which is the most prominent site of tau processing. Quantification of these 
results indicated that the CST- ΔK280 undergoes a more prominent cleavage than 
the other mutated constructs(fig.6).  
 
 
 
Figure 5. Antibodies specificity. Anti-Tau13 antibody targets the 2-18 epitope, anti-Tau5 antibody 
targets the 210-240 epitope, anti-Tau46 targets the 404-441 epitope. Anti-Ser262 Tau and Anti-
Ser356 Tau are respectively targets respectively the first and the fourth repeat domain.  
 
 
 
.  
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Figure 6. Western blot analysis of total protein extracts from wt and mutated CST 
expressing cells. Western blot lanes have been loaded as follows: 1)untransfected cells; 
2)CST;3)CST-ΔK280;4)CST-Q336H;5)CST-At8mut.The full length exogenous proteins are 
indicated at 110kDa, anti-tubulin antibody has been used as loading control. 
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5.CST- ΔK280 is more phosphorylated at Ser262 and Ser356 with respect to CST in HeLa 
cells.  
 
 In order to analyze the phosphorylation profile of CST sensors, Western blot analysis of 
HeLa cells transfected with CST or with mutated constructs have been probed with anti-
pS262 Tau antibody and ant-pS356 Tau antibody(fig.7). 
Quantification with loading controls (gapdh and actin) confirmed that CST-ΔK280 is 
more phosphorylated than the other constructs both in Ser262 and Ser356 
residues. 
On the contrary, the CST is not phosphorylated in HeLa cells. The other mutated 
constructs appeared to be phosphorylated at different degrees. In particular, CST-
Q336H and CST-ΔK280 appeared to be both significantly phosphorylated at 
Ser356. 
 
 
Figure 7. Phosphorylation profile by Western Blot analysis of HeLa cells transfected with the 
CST and the mutated CST constructs. Samples have been loaded as follows 1)untrasfected cells; 
2)CST;3)CST-Q336H;4)CST-ΔK280;5)CST-At8mut. 
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6.Phosphorylation at pSer262 results to be the same in HT22 cells. 
 
In order to analyze the phosphorylation profile of CST sensors in a more significant 
cell type, HT22 hippocampal immortalized neurons have been used.  
Western blot analysis of HT22 cells transfected with CST or with mutated CST 
constructs have been probed with anti-pS262 Tau antibody (fig.8). 
The result indicated that both the mutated constructs are phosphorylated, with CST-
ΔK280 being more phosphorylated than CST-Q336H, as seen in HeLa cells. In 
addition, CST-AT8mut appeared to undergo a more prominent phosphorylation at 
that residue than the other constructs. 
 
Figure 8. Phosphorylation profile by Western blot analysis of HT22 cells transfected with the 
CST and the other mutated constructs. The full length sensor at 110kDa is strongly phosphorylated 
in the CST-AT8mut lane than in the other mutated constructs. Samples have been loaded as follows 
1)untransfected cells; 2)CST;3)CST-ΔK280;4)CST-Q336H;5)CST-At8mut. 
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7.ΔK280 and Q336H mutations displayed a different impact on Tau network complexity. 
 
In order to study the impact of the two mutations on tau network complexity, an 
analysis of the morphological network complexity of tau has been carried out in 
HeLa cells expressing CST, CST-ΔK280 and CST-Q336H (fig.10). Images acquired 
by confocal microscopy have been subjected to image analysis by exploiting the 
IMARIS software that allow to collect two morphological parameters: the total 
filament length (that performs the summing of fluorescent filament segments) and 
the number of branching points (that calculates the number of crossing segments). 
Network complexity analysis indicated that ΔK280 mutation does not alter the total 
filament length and the number of branching points of Tau. 
On the contrary the CST-Q336H analysis revealed an increase in both parameters. 
Indeed, this result indicated an increase in Tau network complexity due to   Q336H 
mutation (fig.9).      
 
Figure 9. Morphological analysis of Tau network complexity in reporter HeLa cells 
expressing CST, CST-ΔK280 and CST-Q336H. Images taken before (1) and after (2) network 
analysis by IMARIS software. 
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Figure 10. Analysis of Tau network complexity in cells expressing CST and mutated 
sensors. Images of (a) CST, (b) CST-Q336H, (c) CST- ΔK280 before (1) and after (2) network 
analysis by IMARIS software. 
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8.CST-ΔK280 has a higher mobility as revealed by FRAP analysis. 
 
In order to analyze the involvement of the two mutations on tau mobility, FRAP 
analysis have been carried out in reporter cells expressing CST-Q336H, CST-
ΔK280 and CST. A selected region of interest in the cells expressing the constructs 
was photo bleached and the recovery rate of the fluorescence intensity, due to the 
mobility of neighboring fluorescent molecules, was evaluated.  
FRAP curves enabled to determine that 87% of CST molecules are in the mobile 
fraction, contributing to fill the bleached area. The recovery curve analysis revealed 
that two main components are represented in the mobile fraction: the 65% ascribed 
to a MTs binding phase that is characterized by a τ1 of 30 sec and the 22% ascribed 
to diffusing soluble molecules with a τ2 of 3,9 sec. Same analysis has been carried 
out for mutated constructs. The CST-Q336H displayed the same mobility as CST, 
indeed the 86% of molecules belong to the mobile fraction, with 64% in a MTs 
binding phase and a τ1 of 31 sec, and the 22% assigned to diffusing soluble 
molecules with a τ2 of 4,2 sec.  
Differently, CST-ΔK280 displayed 90% of molecules in the mobile fraction, with 47% 
ascribed to a MTs binding phase that is characterized by a shorter time of recovery 
(τ1 of 22 sec) and a remarkable increase in the diffusive fraction (43%) and a τ2 of 
2,7 sec (table 1; fig.11). 
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FRAP 
SAMPLE 
MOBILE 
FRACTION(%) 
 FRACTION(%) 
AND TIME(sec) 
STANDARD 
ERROR 
CST 87 fract 1 65  τ1 30,3 
 
0,92 
  fract 2 22  τ2 3,9 0,2598 
 
       
CST-Q336H 86 fract 1 64  τ1 31,3 0,93 
  fract 2 22  τ2 4,22 0,25 
       
CST-ΔK280 90 fract 1 47  τ1 22,2 0,97 
  fract 2 43  τ2 2,7 0,14 
       
 
Table 1. FRAP result of HeLa cells transfected with CST, CST-Q336H and CST-ΔK280.The table 
reports mobile fractions and times of recovery of HeLa cells transfected with indicated constructs. 
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Figure 11. FRAP recovery curves of wt and mutated CST constructs. The blue and the red 
curves represents respectively the CST and the CST-Q336H, showing the same time of recovery. 
The green curve represents CST- ΔK280, with a faster time of recovery than the other two 
constructs. 
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DISCUSSION  
 
 
1.Q336H and ΔK280 mutations impact at different extent tau conformational change. 
 
Mutations in the MAPT locus that influence tau on a protein level have been 
observed to have an impact on its ability to bind to microtubules and in the 
regulation of their network. 
The aim of this thesis is to avail the Conformational-Sensitive Tau Sensor (CST) to 
evaluate the role of Q336H and ΔK280 on protein conformation and its interaction 
with MTs. These two mutations, according to literature, have opposite effects on tau 
binding affinity of the protein to MTs. The first one, ΔK280, affects the gene on 
transcript and on protein level; in the first case inhibiting the insertion of the exon 10 
causing a prevalence in the isoform 3R, in the second case reducing the interaction 
of tau with the MTs and its ability to regulate tubulin assembly. The second 
mutation, Q336H is a very rare mutation that has shown to increase the in vitro MTs 
rate assembly. Only two papers about the Q336H and Q336R mutations have been 
published and the in vitro study suggested a stronger binding affinity. ΔK280 
mutation, on the contrary, has been extensively studied both in vitro and in 
transgenic animals.  The CST displayed a positive FRET signal only when bound to 
MTs, while soluble molecules did not show a significant FRET signal. This 
demonstrated that the CST assumes a specific three-dimensional structure in which 
the C-terminal end approaches the N-terminal end so that the two fluorophores on 
the same molecule display a positive FRET. CST-Q336H showed a positive FRET 
signal too, but with a higher value, thus indicating that the mutated Tau bound the 
MTs assumed a conformation in which the two terminal ends are closer to each 
other. The increased proximity resulted in a more intense FRET signal.  
Thus, our result confirms that, in the cellular context, this mutation has a role in the 
altered three-dimensional conformation of tau on MTs. In order to study the mobility 
of mutated CST, FRAP analysis have been performed. CST-Q336H resulted to 
have the same recovery curve as CST. This result showed that this mutation does 
not affect Tau binding to MTs. On the contrary, a recent study demonstrated that 
Q336H mutation increased Tau MTs binding affinity in vitro (Tacik et al., 2015). Our 
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study demonstrated that, in the context of live cells, the Q336H mutation has a clear 
role in the three-dimensional conformation of tau, but is not involved in the 
regulation of MTs binding.  
 
Moreover, tau/MTs interplay has been investigated by image analysis of fluorescent 
tau network: CST-Q336H showed a significant increase in network complexity, both 
in total filaments length and in number of branching points with respect to CST. The 
increased tau network complexity has to be further analyzed in order to investigate 
the complexity of the relative tubulin network. 
CST-ΔK280 mutation showed a strong reduction of FRET signal, compared to CST, 
indicating that the deletion induced a conformational change in the protein that 
brings the two protein ends far from each other, at least at a distance > 50Å.  
FRAP analysis demonstrated that the mobility of CST-ΔK280 is highly affected. 
Indeed the recovery curve indicated that tau molecules belonging to the MTs bound 
fraction are reduced (from 65 % to 47%) and conversely molecules ascribed to the 
diffusing soluble fraction increased (from 22% to 43%).Moreover, the time of 
recovery of both fractions is reduced suggesting that tau molecules could be 
partially cleaved. In addition, tau/MTs interplay has been investigated by image 
analysis of fluorescent tau network, and ΔK280 mutation resulted to not alter the 
total filament length and the number of branching points of Tau; further investigation 
of the complexity of the relative tubulin network has to be done. 
 
2. Q336H and ΔK280 show different degree of phosphorylation at Ser262/Ser356. 
 
Phosphorylation profile by Western Blot analysis revealed that both CST-Q336H 
and CST-ΔK280 shows positive tau phosphorylation at Ser262/Ser356 in the MT-
binding repeats.  
CST-ΔK280 resulted to be significantly phosphorylated, with a thirty fold increase 
with respect to CST-Q336H in the Ser262 residue, and an eight fold increase in the 
Ser356 residue. According to the literature (Biernat et al., 1993; Biernat and 
Mandelkow 1999; Liu et al., 2007) tau phosphorylation at Ser262/Ser356 residues 
induces tau detachment from MTs.  This suggests that the decrease in MTs binding 
fraction (measured in FRAP experiments) induced by ΔK280 could be also 
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enhanced by phosphorylation at these residues. 
CST-Q336H showed to be more phosphorylated at Ser262/Ser356 five and three 
fold more than CST, respectively. Considering that Q336H displayed the same 
mobility than CST, this suggest that phosphorylation at these residues is not really 
significant for Tau/MTs interplay. The phosphorylation profile of the two mutations 
must be further analyzed to fully assess its impact on tau physiological functions.  
 
 
3. ΔK280 but not Q336H mutation induced Tau protein cleavage in HeLa cells. 
 
Western blot results indicated that ΔK280 deletion induced a more prominent tau 
protein cleavage. It is well known that ΔK280 strongly promotes the aggregation of 
tau into paired-helical filaments (PHFs) because it enhanced the propensity of the 
protein to form β-structure (Barghorn et al., 2000). Indeed, C-terminally truncated 
PHF-core tau has the ability to capture full length tau and to enable sequential 
cycles of binding, truncation and binding, at least in vitro (Flores-Rodriguez et al., 
2015). The observed result suggested that the pro-aggregation behavior of ΔK280 
mutant could be enhanced also by tau truncation. 
On the contrary, Q336H does not induce a prominent tau cleavage, but in patients 
bearing this mutation have been observed to be present aggregates forming Pick 
Bodies, intracytoplasmic inclusions typical of Pick's Disease (Pickering-Brown et al., 
2004; Tacik et al., 2015), indicating that the aggregation process could be 
stimulated also by other mechanisms to be uncovered.  
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FUTURE DIRECTIONS 
 
To fully confirm the characterization of the two mutations, a more extensive study of 
phosphorylated epitopes has to be performed. Moreover, Western Blot analysis 
probed with PHF-1 Tau antibody, which recognizes 396/404 epitopes, will be 
performed, as these sites located in the C-region are known in literature to increase 
MTs assembly activity (Cho and Andrews, 2003; Liu et al., 2007).  
In addition, the preliminary results obtained in this thesis will be further validated in 
vivo. Indeed, to study the role of these two mutations during the onset and the 
progression of tau pathology, in vivo experiments in zebrafish embryos will be 
performed. With transient and stable strategies mutated CST constructs 
(downstream to a neural specific promoter) will be expressed in the nervous system 
allowing to monitor Tau pathology onset and progression by evaluating Tau 
conformational changes at different stages. 
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